Today, we sit down with Robin McIntosh, the visionary founder of Workit Health. Founded in 2015 by Robin and her co-founder Lisa McLaughlin, both women in long-term recovery from addiction, Workit Health has emerged as a trailblazer in the field of addiction treatment. Driven by their firsthand experiences with America's fractured treatment system, Robin and Lisa set out to create a more effective and accessible approach to care.
At the heart of Workit Health's mission lies a commitment to measurement-based care, ensuring that their innovative strategies translate into improved outcomes for individuals battling addiction. The company's research team, Workit Labs, brings together a diverse group of experts dedicated to advancing the understanding of substance use disorder treatment through rigorous scientific research and analysis.
In a groundbreaking study, Workit Health recently assessed the effectiveness of telemedicine treatment for opioid use disorder (OUD) among rural Americans in the post-COVID era. The findings not only underscore the efficacy of their care model but also shed light on the transformative potential of telemedicine in reaching underserved populations.
Throughout the interview, Robin shares valuable insights into the challenges and triumphs of pioneering a new approach to addiction treatment. She delves into the importance of empathy, innovation, and data-driven decision-making in revolutionizing the landscape of care. With a steadfast commitment to sharing their discoveries with the wider healthcare community, Robin and the Workit Health team are paving the way for a brighter future in addiction recovery.
Robin McIntosh, Chairperson & Co-founder, Workit Health
Megan Antonelli, Chief Executive Officer, HealthIMPACT Live
[00:00:00] VO: Welcome to Digital Health talks. Each week, we meet with the healthcare leaders making an immeasurable difference in equity, access and quality. Hear about what tech is worth investing in and what isn't. As we focus on the innovations that deliver. Join Megan Antonelli, Janae sharp and Shahid Shah for a weekly no BS deep dive on what's really making an impact in healthcare.
[00:00:30] Megan Antonelli: Hi, Welcome to Health Impact, live digital health talks podcast. I'm your host. Megan Antonelli, bringing you insights from Healthcare's most innovative leaders. Today, we are joined by Robin McIntosh, co founder and chairperson of work at health, a pioneer in telemedicine addiction treatment. Robin's journey from personal recovery to revolutionary care delivery is both inspiring and transformative. Let's dive in. Hi Robin. How are you today?
[00:00:55] Robin McIntosh : Hi, I'm great. How are you doing? It's so nice to be here. Thank you for having me. Absolutely.
[00:01:00] Megan Antonelli: We're so excited to have you, and I've just, I've heard the story of work at health, and I'm excited to learn more. So tell me, you know I think you have another co founder, Lisa. Tell me about your you know, what experiences and what inspired you to found work at health?
[00:01:17] Robin McIntosh: Sure. So, gosh, where, where to begin? So I so we, really, we started work at health in earnest in 2015 and it feels like such a long time ago now, but we started it against the backdrop of digital health just taking root and right here in San Francisco. And really, we started it out of my apartment in Oakland, and Lisa and I had known each other for quite a while in AA, so in Alcoholics Anonymous, and a very long time. So I met her, actually in 2009 and we were very close from the start and and so we so she was just taking a she was just taking a hiatus, like a career sabbatical, and thinking about her next moves. And for me, I had a design studio with a woman named Kate Harris, and I actually just sent you the link before this, because it's an amazing design studio, and I loved my job. I love siren. It's awesome. We were just doing all of these really interesting creative projects, but one of the one of the incubators we worked with in San Francisco was incubating digital health companies, and it's called Rock Health, and now they're more of a venture studio. So we got to work with a lot of the early rock health companies, and it was such an exciting time, especially Hallie TECO had created Rock Health, and they had this little Chinatown office, and she had such a vision for how healthcare was going to unfold in the next, like, 1015, years, like she truly is one of those preternatural talents, and I learned so much from watching her, and learned so much from the companies that were creating these self driving cars of healthcare. You know, we worked on diabetes and we worked on oncology apps, and we worked on all sorts of different interventions, but one thing that I found really striking was that nobody was working on addiction, and this was in stark contrast to my day to day, kind of, the fabric of my everyday, where I had a lot of friends that were relapsing. I went to a lot of funerals, as did Lisa. And it was just strange. It was just something that nobody really talked about. And when you talk to health plans, this is hard to believe now, but when you when you talk to health plans and people that were sort of tasked with providing holistic, like, kind of wraparound care for these conditions, they commonly said, we don't really see addiction problems, and that's because of the way our fee for service structure works, and kind of the guts of American health care. If you don't see it in your claims, it's not there. And I think a lot of us and a lot of people in health plans to be sure, were a little fed up with that narrative, considering it felt like the walls were closing in and encroaching upon like our day to day existence, like everybody has, somebody that has struggled with addiction. So Lisa and I got together around my around my dining room table in my apartment in Oakland. I was young. It was still my quantities, and so I was just naive enough to do it, you know? And I think that's really important, and it's an important part of our story, where we were basically looking at the world and saying, This is broken. Everybody's funneling, being funneled to inpatient rehab. Why is nobody putting this online? Like, why? Why can I order pizza in the middle of the night from Uber Eats or whatever? You know, ride sharing was big at the time, and Lyft was going around with the mustaches and things like that. And we said, why isn't it that easy to access gold standard care? You know, this is not rocket science. And, you know, I think it was a case of us feeling like, are we the smartest people in the room, or the dumbest people, then I commonly feel like that. I'm like, do I have this genius idea, or is it like, why has nobody done this? Like, am I missing something? But we are just naive enough to do it, and we ended up starting working in that way. So very much, like looking at the problem diving, diving, diving. To the research. Lisa's a very brilliant co founder, like she, she just inspires me endlessly. And we just dove right in. And so we spent a good, though, couple of years really researching the problem versus coming at it with a solution in hand, like we were sort of ideating around lived experience, wading through a problem, saying, like, what could help, and throwing different ideas together and through beta testing. So, so that's, that's how we started, with a very organic way to start,
[00:05:30] Megan Antonelli: Yeah, well, what a great way, and what a great time it was in in San Francisco at that time. And that's so cool. I didn't realize that you guys had worked with rock, you know, rock, health and stuff. But that was certainly, you know, sort of that, that really fun time in digital health, but, you know, and what a cool story. Tell me a little bit about what does make it different, other than it being a digital platform, what are some of the key elements that that you think you know, create that make it a successful platform?
[00:06:00] Robin McIntosh: Sure, and I have so much more knowledge now, I didn't realize what made it different at the time and what made it unique, but work at least, and I have a lot of mutual respect and love for one another, and especially at that time. And so we really founded it as like a function of our own existence and we really founded it with mission first. So a lot of the decisions we made later, especially so especially in the last couple of years the mission, I was just having a conversation about this, but the mission, the reason we started the company, governs a lot of the big decisions we made later. So I can talk a little bit about that, but setting that DNA is so distinct from somebody that's rolling out of Stanford. Stanford has a lot of incredible programming, but, like, somebody that's rolling out of an MBA program somewhere that wants to create a company, because startups are the hot thing. Like, I didn't know that there was this, like, world around startups. I really just thought Rock Health is cool. Like, Rock Health is great. I was a designer, and Lisa was an education and she, you know, she was an academic, and, like, I, I didn't realize there was this whole industry around conferences and startups. Like, I didn't do it for the money. I really did it because nobody else was touching it. I really did it because I thought it deserved to be in the world some sort of other solution between, like, dying, right rehab, and then what, like white knuckling it by yourself and, and I'm a maker, I like to make so that that's different and that every decision we make later, you know, we've raised a lot of money now, and work, it's profitable, and, you know, it's a much bigger company, but every decision is still rooted in that DNA. So when I think about founding companies, and when I think about those early days, you are really setting the dynamics of the business for later on. But that's different. I think that's different,
[00:07:53] Megan Antonelli: Right? Well, yeah, and you as as a both a patient and a designer coming at it in that in that scope. So that's, that's really great. And I, you know, I mean, I think broadly, America's approach to mental health is never been a good one, both either, you know, and so where addiction fits into that, you know, has even been more sort of neglectful and turning the other eye, right, so, but I know there's a little bit in terms of kind of that measurement based care model. Can you tell us a little bit more about that and how that works with the treatment programs and approaches?
[00:08:31] Robin McIntosh: Sure, and I think this is also rooted in the context in which we were building, but it was always very important. So for me, personally, I've been to a bunch of different inpatient rehab centers. My first one was 17 and and then my last one was in Arizona. Actually, my last one was in California, but my second to last one was in Arizona, and it was $60,000 like back in the olden days, before inflation. So it must be like 120 now, you know, like, you know, it was really expensive. All private pay, my insurance didn't pay any any piece of it, so it was really expensive. All private pay. It was like my third or fourth, fourth place too. And so that made it complicated for my family, thinking like, is this going to work? Is this going to work? So we were probably a little bit more, especially my parents. And I was really young. I was not even I just had turned 21 and so my parents were more involved than they would be now, you know, in my 30s. But so with my parents, they were, especially my dad, kind of questioning this rehab center, saying, What are the outcomes like? What are the outcomes? Is this going to work for her? And they very much claimed, like they very much felt okay, and I can't believe that it's permissible to do this, saying we really don't know, like we really don't do longitudinal studies in that way. We find that it's successful, but we can't really give you any scientific measurement. And this still happens. Like I, a close family member, just went to a private pay rehab on the beach in Orange County, and I. Called them for her and said, Well, what's your measurement based care strategy? And they were like, we don't, we don't do that. They don't have one. So I think, I think in these conditions, especially in these specialty care conditions, especially addiction, you're so you're fighting for your life, and you will do anything to help a family member or friend yourself kind of survive. And so unfortunately, kind of the private pay industry has moved around that and kind of not, I think the road to hell is paved with good intentions. It's one of those situations. It's not like there's a nefarious actor pulling the strings of everyone, but I think, like kind of the private pay industry has be created a black box where there should be a lot of transparency. Now, with the other thing with addiction, it's hard to have measurement based care, because you have such a transient population people relapse. It's not a one and done deal. The addiction is for life. It's a chronic thing, and you have to, you know, I work on my recovery every day, whether I like to or not. That's just, that's just what I have to do until, until I die. So it feels different now because it's so interwoven, but so that's another thing that's complicated. It's hard to keep track of people. Now, when the digital health era started, and work it started we were the first, we were, by far, the first digital app for addiction, aside from a few other lifestyle ones, we were the first healthcare one, and so at least we thought so at the time. I'm sure other people think they're the first two. But so with the work it, though, we really committed from the beginning to to transparent outcomes. So we said, and this was an opportunity, and still is, that digital provides when you have somebody that's logging in every day, meeting with your nurse practitioners and your MDS and their care team through video, you can track them so much easier than if it's an in person experience, right? Because it's your phone. The phone is always with you through any situation. If you move residences, if you change careers, et cetera, you still have your phone and your phone number, sort of, we're tied to these objects, and that allows us to do a lot of deep, data, intensive work on on how we're affecting change in the lives of our patients. So when we talk about measurement based care, I think it's more important than ever, especially especially as we see the kind of the digital health world advance, it's more important than ever to think through, what outcomes are we measuring, and are we really moving the needle, and how objective can we get? And the most objective thing, of course, would be like a blood test to see, but you can't always do that so, but it's a whole interesting so work it. You know, we we take a PHQ nine for depression. We do a lot of anxiety screenings. We also use something called the substance use recovery evaluator, the sure to to ensure that people are meeting the goals that they set for themselves. Those kinds of things, but we're very much committed to it, and we have a whole research department. From the beginning, we've always prioritized research, and working with NIDA and some of our grant initiatives, we've always prioritized measurement based care, so we have about a decade of longitudinal data, which is really, really novel and helpful.
[00:13:09] Megan Antonelli: It's amazing. Yeah, it's crazy. I mean, I was, I was a biopsychology major in college, and then I one of the first conferences that I really fell in love with was a behavioral health outcomes management conference. So, you know, I know there was a lot of work being done then, and that was a long time ago around, you know, measurement and it, you know, and it was, it's, it's sort of in these walls of academia, but not necessarily in clinical practice, you know. And I don't know that, you know, I mean, it still sort of lives there, right? I think that so strange, right, right? I mean, because it's certainly people have a have a, there's a discipline around it, but it is hard to quantify. And it is, I think your point around tracking those populations is challenging. And then, of course, the, you know, the care system around that, around it is so siloed and disparate and not sort of continuous, and necessarily part of the, you know, mainstream healthcare or what have you. So it makes it all that much harder. So what are some of the you know things that you're seeing? I mean, I always think, you know, particularly with digital health, that that mental health is one of the best you know applications, because I think it just does create accessibility where there's literally none. I mean, growing up in New York was different because, yes, there were a lot of therapists, a lot of psychologists and a lot of psychiatrists available, although a lot of it private pay, it was still available here. I always joke in Southern California that I can find a hypnotist faster than I can find or perhaps a medium, yeah, it's true. Yeah, a crystal shop. You know, I can get my sound bath much faster than I can get a therapist. I still. So, you know, digital platforms have been, you know, a game changer with young kids and all of that. And of course, then during the pandemic, right? I mean, there was everything had to sort of go to telemedicine for that. So tell me, you know, a little bit in terms of having done this for now. You know, had been in play for 10 years, but then obviously, lots of change and adoption happening during the during the pandemic, you know, what are some of the findings that you're seeing from that?
[00:15:29] Robin McIntosh: I think it depends on, you know, it's such a big question, such a great question. I think it really depends on where you look like I I've seen a lot of stages of it, you know. And I really, we started siren back in 2012 so we started siren, Kate and I right before the boom. So, right? You know, before Rock Health, like before everything sort of congealed and came together. So it goes in, like, these optimism, hype cycle stages, and it kind of reflects the market. But healthcare is so resilient, and it just keeps going, right? Like, not like we have, it's not like a new shoe or something. It's not like a trend, like it just keeps going. We keep addiction, just keeps raging on, unfortunately, and, you know, and then also wellness solutions and the need for better care. So I think overall, when I look from a clinical efficacy perspective at the industry, you have like two kind of counter forces happening. And I'm kind of speaking off the cuff a little bit, but so one, one is this adherence to measurement, measurement based care. So this idea that digital because of kind of because it is digital, and it will always fight for its place in the sun, against in person, because we have a bias towards in person things, and we have a bias towards the past. We just always will do especially in scary life or death situations. We will always, sort of, as humans, fall back to what feels really comfortable. And so you I see the beginnings of holding digital to a really high standard, much higher than, say that inpatient rehab I'm talking about now. That's great. I think it's great to hold digital company to higher standards than in person. Often, like, sometimes I go to the doctor's office and I'm like, I can't believe they're getting away with this, like yelling my name across the waiting room and things like that. And you're like, This is shocking. And I've been in a lot of medical settings lately, especially at pediatric behavioral health, because I have two daughters, and I'm just like, this is the HIPAA nightmare, and this is the HIPAA nightmare. I'm the worst. You're looking at the worst. I'm always like, the HIPAA police, but, but I love that about digital. Now, the flip side, though, of course, is that it kind of strangles innovation. And so you had a lot of bad actors in covid. You really did. You had really egregious actors doing crazy things, like prescribing things like candy or pushing doctors to kind of look the other way on certain chart, details like just really egregious things. Now that has kind of put a stain in my mind on the industry and led to a lot of like crackdown innovation, crackdown on innovation. And so you unfortunately were in this kind of winter of innovation, where I'm looking at the world thinking like, where is where's that? 2014 2015 energy, right? And like, yes, you have measurement based care, but you don't want so much that it becomes a glacial healthcare company again, where it takes 10 years to put out a study that says something that we all knew to be true anyway. So I think we need to walk the line like we definitely need to walk the line. And I think a lot of like the new I think we're going to see this a lot in AI especially like a lot of the new technology. And the promise of the new technology is immense and powerful. But if we get in there and kind of say, nobody can make mistakes and nobody can innovate and everything has to be pushed through a regulatory process, we're just, we're going to stay in the stone ages. And we're already in the stone ages of healthcare in America. We have a horrible track record of healthcare for being, you know, for having the resources we do at the country. Our population health metrics are, like, woefully behind other countries. And so I think, I think having like, kind of insight into what the future brings and yields and requires is going to be really important. So I think a lot about that. And then there's a whole nother topic, which is kind of the investor landscape and funding, which is, you know, something we can get into or not depending on your appetite.
[00:19:24] Megan Antonelli: Yeah, no, I mean, well, I think, you know, to talk a little bit more about kind of the value and evidence, right? So we work with a group called node health, the network of digital evidence. And there's, you know, and we that started in 20, I think, 2016 2017 like, right around there where it was, like, you know, here we are. We're doing all these implementations, doing a lot of, you know, investment into digital health. But where is the evidence? Where is the value? And then now, you know, almost 10 years later, you've seen this, you know, you've kind of seen the it. The pendulum swing. As you said, I think that with the pandemic, it was like, Just do it. It's amazing. It's great. And then there was, like, a visible of some, you know, where we had to to sort of peel back. But now, you know, and as you said, with investors, whether they're for the purchasers of this, of the software, the applications, the services, or people putting, you know, when companies putting money into it, wanting to know, where is the value, but at the same time, digital is sort of ubiquitous, and it's everything and and in some ways, you know, the patients are also demanding it, right? I mean, that's the way they're in some cases. So I'm curious, you know, what you think about, kind of that intersection of, you know, what patients want and what is truly working, you know, particularly with addiction. I mean, I think we're seeing, you know, certainly right now with, you know, sort of the sober, curious movement and people, you know that there was this such a, you know, sort of a stigma to addiction treatment. And there was one way to do it in many cases, and now there's many applications, many tools. So when you think about kind of the advancements, both, you know, and this is a big question, we could talk about it probably all day, both like culturally, but also, you know, from a from true clinical practice, you know, where, where is, where are we seeing the most impact on, you know, addiction treatment,
[00:21:29] Robin McIntosh: Interesting. I think, I mean, I would like to, I'm biased, but I would love to say digital. It's, I have a different view right now, I think because of the way the market is going and the lack of innovation. So I think, I think the companies that prioritize, so I'll talk from a kind of a health plan perspective, I think the companies that prioritize novel, innovative models of care are going to eventually come out on top. I don't think we've found the Shangri La yet. You know, I think we need to prioritize innovation and and just as much as like measurement based care and kind of let people kind of experiment. Now there's this whole push towards value based care as well, of course. And I think that the digital world has a better ability to really because, because with in digital everything is open source and everything is Mali in malleable. So if we want to stand up a new, innovative drug testing methodology that's super convenient for people that says, Okay, this is going to work on the lowest Wi Fi, you know, the lowest broadband that we can possibly do. We can do that in three months versus a brick and mortar clinic changing, you know, building up a site and all of those, like all of the other things that come with, like, kind of the brick and mortar model, so we can push innovation farther. And so I think, I think the more that we move towards consumer based healthcare, and the more that we have agency over the choices that we make as people that are kind of sculpting our health plans and sculpting our premiums, and like paying for things and paying out of pocket, the better it's going to be. So I don't know, though it's an interesting time like I I find that, and I know I'm part of the female founder series. I'm very proud of that I find, and I have a lot of friends, you know, I I'm a very like gregarious person, and a lot of ways, are very curious, so I ask a lot of questions, and I have a lot of friends that are either raising money right now or raising bridge rounds or continuing, and I'm finding that and finding that investors are really, really skittish around digital health. There's this clamp down, and this feeling of like, well, there have been investors are very impatient, so there hasn't been a big exit. So we're going to clamp down. We're not going to invest in digital health anymore. So you sort of have, so what do you do? Right? So you have this, like, consumer appetite, so you have the people, like, a thing, we want to be sober, curious or, you know, I want to do this in a different way. I don't want to go to my doctor's office and be called across the waiting room. Wait there an hour across town, you know, I'd rather be private. I would rather actually, like, you know, I'd rather do this than a private way that honors my right to privacy and but then you have this, you know, largely those innovations come from the venture markets and they come from startups. Then you have this clamp down. So we'll see how those two forces, like kind of combine like this, like need for innovation and this, like appetite, plus this, like reluctance to fund it'll be interesting to see. Yeah, I think it's setting the stage for some great companies, but it they're going to look significantly different than, I think, the noisy companies of the past working included,
[00:24:36] Megan Antonelli: Sure. I mean, you know, and that's so two things. I mean, I wanted to sort of, when we talk about the investor market and and kind of that they're skittish around digital health. And then at the same time, I think there has been, in the last at least 12 to 16 months, a certain exuberance around artificial intelligence and generative AI, and what that's kind of pumping in and to help. Care and the capabilities. And one of the things that I think is interesting, and I think it has some relevance here, is, you know, I've heard people talk about how what AI will do through assistive AI is to tackle some of the things that we couldn't afford to do before, right? So it's obviously not going to give the deep empathy that a you know practitioner can give, or you know, expensive diagnostic tests at some very you know, deep level, but that kind of regular check in that a bot could do, or the you know, the you know, and also some measurements and tracking and identifying triggers you know that those things will be, it will be capable of, and maybe ultimately, as we were talking about, make the measurement of outcomes possible, right? Because we'll be capturing more data. And that ability to capture the data and not overwhelm the system, but be able to actually process it, to then make decisions or or get insights from it. So with that in mind, with that sort of exuberance around the technology that's possible and where it's coming, and then your experience and your knowledge of the current investor models, you know, investor not models, but attitudes behaviors. You know, where do you think things are headed? And you know, where are you giving the advice to other female founders who might be out there just getting started, or to, you know, to yourself as you, you know, continue to grow the organization.
[00:26:26] Robin McIntosh: Yeah, no. Great question. I think, I think AI is so promising and so fascinating, and I'm always an early adopter. Like, I'm the person that every time there's new iPhone, like, I got a new, you know, I I always love technology. And I think I like, I like modern day wizardry, like, I like the feeling of the magic that that tech can create. And when you, when you tear away all of like, the bullshit around tech, sorry to say that. But so when I think about AI and house, so I have a mouth like a sailor. I curse all the time, and I'm really trying, because I have a little my four year old now is, like, smart enough to catch me, and she's, like, she doesn't even allow me to say stupid, like, Mama, that is a bad blood. That's a bad blood. That's a problem. Like, oh, she's our little ball buster, but it's a peach and so. But anyway about AI, I think, I think that everybody, at least I know, the people that are in the companies like work that, or the companies that are in like kind of the, you know, the 25 to 100 million range, like that kind of, that kind of series B plus company. Those companies have a hard road ahead, integrating AI in a meaningful way into their stack, into their kind of work stack, and their operative stack. And that's really coming off of what was a pretty and still going insane beat down digital health, whether merited or not, right, like, whether necessary or not, in some ways, like absolutely a reckoning was was needed, and other ways. Everyone is very, very scared. So I don't know if we're really the all the big come, all of the companies that got that made it through this winter, and now are, you know, in a post a series a post Series B state. I don't know if we're gonna see them be able to deploy AI in a really earth shattering, like groundbreaking way. Now, I think the a the companies that are being created right now, if they can get funded, those are the companies to watch. So I think AI is one of those things like the internet, like either your digital or brick and mortar, and that DNA is said at the beginning, not to say that a company can't evolve, but once your DNA is set, it's brick and mortar will always have an appendage of digital, and digital will always have an appendage of brick and mortar. And mortar, and typically it doesn't go that way because it's cost prohibitive. AI, like to be a truly generative chat bot, something like that, you need to build that from the start, you know, because it's so regulated now and it's so touchy, like work it, we have so many strict measurement, measurement based care protocols, like, we're an actual company, so that's how I think about it, like, I think we're going to see some effective AI in those companies, but it's only going to be marginal. So I'm excited for this new kind of rash of startups. I'm excited to see what kind of emerges onto the scene, um, and I'm hoping that, you know, from a female founder perspective, I think we commonly get either turnaround companies or like, you know, you get investors wanting to bet on you, but they want to bet on you, not for your moonshot, but for your safe bet. So I'm hoping that we can kind of change that story as well. So those are the things I've been thinking about lately. Thank you.
[00:29:40] Megan Antonelli: Well, I love that, and I hope, I hope for that as well. In terms of, you know, just where you see work, it sort of evolving and heading to, what is your, you know, what is the future state? What are the are there things that you're super excited you're working on right now? What what's to come? What we should, what should we be looking for?
[00:30:00] Robin McIntosh: I think work it is so interesting, and that I almost it's, it's one of those organic things where you don't know why you still have patient as designers at the center of it, but it is like, if you go into work culture, if you go into a work a day, like, we still have recovery meetings for the staff that I attend, right? Like, we just, it's such a rich culture. So, so I'm excited as work it gets a lot larger and works with Medicaid and commercial plans across the country. I'm excited to keep that notion of nothing for us without us center stage like it's fun to see that kind of expand out. You know, our chief medical officer talked quite a bit as quite a bit from the role of being chief medical officer, but being inspired by the idea of patient as designers, and it's very cool. So I see work at just continuing to serve as many people as humanly possible and and to curry favor and build up trust with health plans to do so, I think it's important that work clinical quality has always been our number one prerogative, despite everything, like all the ups and downs over the years, and I don't see that going away, but, but, yeah, so I think, I think that's in the future, and then, you know, and what that looks like will be really interesting. We have a lot of really interesting things coming up. The DEA have to give us their final decision about in person requirements for controlled substances. We have aI coming onto the scene. I think there's a lot of partnership opportunity there. You also have this bringing down. I mean, it's, it's, it's small and incremental, but it's meaningful. You have this like, kind of dissipation of the stigma a little bit. And so you have primary care groups and hospital systems now going to work it and say, Hey, can you augment my more general care practices with your specialty intervention? That's really exciting as well. So I think the future is bright, and I don't know it's fun to be a real company now, 10 years later.
[00:31:56] Megan Antonelli: Oh, you actually found it in 2015 too. So it is, it's like only yesterday, but it feels like a long time, right? Well, I'm excited to see what you'll bring to it as well. I'm sure it will be great, and the future is bright. Tell our audience how to get in touch with you and how to find more information about work at health.
[00:32:15] Robin McIntosh: Sure. So you can just go to our website at www. Dot work. It helps.com. Work, it is. It works. If you work it, that's where it's from, from that AAA adage and, and, yeah, so I'm on the work it website. I write for our blog frequently. Robin at work. It help.com and, yeah, that's how to get in touch.
[00:32:36] Megan Antonelli: Awesome. Well, thank you so much, Robin. It's been a pleasure to talk to you and learn about both your experience and you know all the great work you're doing at work at health and thank you to our listeners for tuning in to health impact live digital health talks podcast. I hope you enjoyed Robin's insights and the work that she's doing, revolutionizing addiction treatment through telemedicine is truly inspiring. So join us next time as we continue exploring Healthcare's digital frontier, I'm Megan Antonelli, signing off.
[00:33:06] VO: Thank you for joining us for this week's health impacts digital health talk. Don't miss another podcast. Subscribe@digitalhealthtalks.com and to join us at our Next face to face event, visit healthimpactlive.com